Distinct lipid/lipoprotein profiles and hormonal responsiveness in nine ethnic groups of postmenopausal Asian women: The Pan-Asia Menopause (PAM) study

Climacteric

Volumn 10, Issue 3, 2007, Pages 225-237

  Taechakraichana, N ^a   Holinka, C F ^b   Haines, C J ^c   Subramaniam, R ^d   Tian, X W ^e   Ausmanas, M K ^e  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b PharmConsult   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d Fetal Medicine and Gynecology Center   (Malaysia)

^e PFIZER INC   (United States)

Author keywords

Hormone therapy; Lipid profiles; Menopause; PAM study; Pan Asia Menopause study; Postmenopausal Asian women

Indexed keywords

CALCIUM; CHOLESTEROL; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ASIAN; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; HORMONE RESPONSE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MENOPAUSE; MULTICENTER STUDY; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRIGLYCERIDES; WOMEN'S HEALTH;

EID: 34248588082     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701352375     Document Type: Article

References (58)

1. Grundy SM, Cleeman JI, Merz CNB, et al. For the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
2. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2001;104:1108-13
3. Verschuren WMM, Jacobs DR, Bloemberg BPM, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five year follow-up of the Seven Countries Study. JAMA 1995;274:131-6
4. Manson JE, Tosteson H, Ridker PM, et al. The primary prevention of myocardial infarction. N Engl J Med 1992;326:1406-16
5. Wilson PWF, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality: The Framingham Heart Study. Atherosclerosis 1988;8:737-41
6. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124:S11-20
7. Nicholls SJ, Nissen SE. Strategies to promote HDL-C: an emerging therapeutic agent. Eur Heart J 2005;26:853-5
8. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-8
9. He Y, Lam TH, Li LS, Li LS, He SF, Liang BQ. Triglyceride and coronary heart disease mortality in a 24-year follow-up study in Xi'an, China. Ann Epidemiol 2004;14:1-7
10. Futterman LG, Lemberg L. Lp(a) lipoprotein - an independent risk factor for coronary heart disease after menopause. Am J Crit Care 2001;10:63-7
11. Berglund L, Ramakrishnan R. Lipoprotein(a) an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004;24:2219-26
12. Tatsanavivat P, Klungboonkrong V, Chirawatkul A, et al. Prevalence of coronary heart disease and major cardiovascular risk factors in Thailand. Int J Epidemiol 1998;27:405-9
13. The InterASIA Collaborative Group. Cardiovascular risk factor levels in urban and rural Thailand - The International Collaborative Study on Cardiovascular Disease in Asia (InterASIA). Eur J Cardiovasc Prev Rehabil 2003;10:249-75
14. Nitiyanant W, Ploybutr S, Harntong S, Wasuwat S. Tandhanand S. Lipid and lipoprotein contents in normal Thai subjects. J Med Assoc Thai 1987;70:20-3
15. Yamwong P, Assantachai P, Amornrat A. Prevalence of dyslipidemia in the elderly in rural areas of Thailand. SE Asian J Trop Med Publ Health 2000;31:158-62
16. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in a population with low cholesterol concentrations. Br Med J 1991;303:276-82
17. Wu Z, Yao C, Zhao D, et al. Cardiovascular disease risk factor levels and their relations to CVD rates in China - results of Sino-MONICA project. Eur J Cardiovasc Prev Rehabil 2004;11:275-83
18. Tao S, Li Y, Xiao Z, et al. Serum lipids and their correlates in Chinese urban and rural populations of Beijing and Guangzhou. Int J Epidemiol 1992;21:893-903
19. Janus ED, Postiglione A, Singh RB, Lewis B. The modernization of Asia. Implications for coronary heart disease. Circulation 1996;94:2671-3
20. Stefanick ML. Risk-benefit profiles of raloxifene for women. N Engl J Med 2006;355:190-2
21. Rosengren A, Hawken S, Ôunpuu S, et al. For the INTERHEART investigators. Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:953-62
22. Yusuf S, Hawken S, Ôunpuu S, et al. For the INTERHEART Study investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52
23. Tan D, Haines CJ, Limpaphayom KK, Holinka CF, Ausmanas MK. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia Menopause (PAM) study. Maturitas 2005;52:35-51
24. Haines CJ, Xing S-M, Park K-H, Holinka CF, Ausmanas MK. Prevalence of menopausal symptoms in different groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: The Pan-Asia Menopause (PAM) study. Maturitas 2005;52:264-76
25. Limpahayom KK, Darmasetiawan MS, Hussain RI, Burriss SW, Holinka CF, Ausmanas MK. Differential prevalence of quality-of-life categories in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogestorone acetate: the Pan-Asia Menopause (PAM) study. Climacteric 2006;9:1-11
26. Haines C, Chung T, Chang A, Masarei J, Tomlinson B, Wong E. Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. Arch Intern Med 1996;156:866-72
27. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-1 and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005;294:326-33
28. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33
29. Jungner I, Sniderman AD, Furberg C, Aastveit AH, Holme I, Walldius G. Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction? Am J Cardiol 2006;97:943-6
30. Sniderman AD, Junger I, Holme I, Aastveit A, Walldius G. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-1 ratio to identify the lipoprotein-related risk of vascular disease. J Intern Med 2006;259:455-61
31. Chew WLS, Mah PK, Tan YT, Cheong CK. A comparison of the levels of total serum cholesterol (1974-1984) and its relations to ischaemic heart disease in Singapore and the United States of America. Sing Med J 1988;29:6-10
32. Dwyer T, Emmanuel SC, Janus ED, Wu Z, Hynes KL, Zhang C. The emergence of coronary heart disease in populations of Chinese descent. Atherosclerosis 2003;67:303-10
33. Woo KS, Chook P, Young RP, Sanderson JE. New risk factors for coronary heart disease in Asia. Int J Cardiol 1997;62(Suppl 1):S39-42
34. Khor GL. Cardiovascular epidemiology in the Asia-Pacific region. Asia Pac J Clin Nutr 2001;10:76-80
35. Zhou BF, Stamler J, Dennis B, et al. Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the late 1990s: The INTERMAP Study. J Hum Hypertens 2003;17:623-30
36. Pan W-H, Chiang BN. Plasma lipid profiles and epidemiology of atherosclerotic diseases in Taiwan - a unique experience. Atherosclerosis 1995;118:285-95
37. Williams B. Westernised Asians and cardiovascular disease: nature or nurture. Lancet 1995;345:401-2
38. Khoo KL, Tan H, Liew YM, Deslypere JP, Janus E. Lipids and coronary heart disease in Asia. Atherosclerosis 2003;169:1-10
39. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998;97:596-601
40. Bhatnagar D, Anand IS, Durrington PN, et al. Coronary risk factors in people from the Indian subcontinent living in West London and their siblings in India. Lancet 1995;345:405-9
41. Hughes K, Lun KC, Yeo PPB. Cardiovascular diseases in Chinese, Malays, and Indians in Singapore. I. Differences in mortality. J Epidemiol Commun Health 1990;44:24-8
42. Hughes K, Yeo PPB, Lun KC, et al. Cardiovascular diseases in Chinese, Malays, and Indians in Singapore. II. Differences in risk factor levels. J Epidemiol Commun Health 1990;44:29-35
43. Wild SH, Laws A, Fortmann SP, Varady AN, Byrne CD. Mortality from coronary heart disease and stroke for six ethnic groups in California, 1985 to 1990. Ann Epidemiol 1995;5:432-9
44. Balarajan R. Ethnicity and variations in mortality from coronary heart disease. Health Trends 1996;28:45-51
45. Sheth T, Nair C, Nargundkar M, Anand S, Yusuf S. Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths. Can Med Assoc J 1999;161:132-8
46. Anand SS, Yusuf S, Vuksan V, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet 2000;356:279-84
47. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001;76:13-24
48. Chang T-C, Lien Y-R, Chen M, Cheng S-P, Chen R-J, Chow S-N. Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study. Acta Obstet Gynecol Scand 2004;83:661-6
49. Haines CJ, Chung TKH, Masarei JRL, Tomlinson B, Lau JTF. An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein(a) and other lipoproteins. Atherosclerosis 1996;119:215-22
50. Barrett-Connor E. Hormone replacement therapy, heart disease, and other considerations. Ann Rev Publ Health 1998;19:55-72
51. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33
52. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9
53. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study Follow-up (HERS II). JAMA 2002;288:49-57
54. Hodis HN, Mack WJ, Lobo R. What is the cardioprotective role of hormone replacement therapy? Curr Atheroscler Rep 2003;5:56-66
55. Naftolin F, Taylor HS, Karas R, et al. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004;81:1498-1501
56. Pines A, Sturdee DW, Birkhäuser M. on behalf of the International Menopause Society. More data on hormone therapy and coronary heart disease: Comments on recent publications from the WHI and Nurses' Health Study. Climacteric 2006;9:75-6
57. Manson JE, Bassuk SS, Harman SM, et al. Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 2006;13:139-47
58. Leowattana W, Bhuripanyo K, Worawattananon P, Mahanonda N, Pokum S. Correlation of serum lipoprotein(a) with the clinical presentation of Thai coronary artery disease patients. J Med Assoc Thai 2000;83(Suppl 2):S194-8